253 related articles for article (PubMed ID: 33400690)
1. Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
Hirozane T; Masuda M; Sugano T; Sekita T; Goto N; Aoyama T; Sakagami T; Uno Y; Moriyama H; Sawa M; Asano N; Nakamura M; Matsumoto M; Nakayama R; Kondo T; Kawai A; Kobayashi E; Yamada T
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33400690
[TBL] [Abstract][Full Text] [Related]
2. TNIK inhibition abrogates colorectal cancer stemness.
Masuda M; Uno Y; Ohbayashi N; Ohata H; Mimata A; Kukimoto-Niino M; Moriyama H; Kashimoto S; Inoue T; Goto N; Okamoto K; Shirouzu M; Sawa M; Yamada T
Nat Commun; 2016 Aug; 7():12586. PubMed ID: 27562646
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.
Lee Y; Jung JI; Park KY; Kim SA; Kim J
Oncotarget; 2017 Jun; 8(25):41091-41101. PubMed ID: 28467797
[TBL] [Abstract][Full Text] [Related]
4. Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT).
Sun Y; Gao X; Wu P; Wink M; Li J; Dian L; Liang Z
Phytomedicine; 2019 Oct; 63():153015. PubMed ID: 31302315
[TBL] [Abstract][Full Text] [Related]
5. PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.
Basu-Roy U; Han E; Rattanakorn K; Gadi A; Verma N; Maurizi G; Gunaratne PH; Coarfa C; Kennedy OD; Garabedian MJ; Basilico C; Mansukhani A
Oncotarget; 2016 Sep; 7(38):60954-60970. PubMed ID: 27528232
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3,4-Dihydrobenzo[
Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886
[TBL] [Abstract][Full Text] [Related]
7. Emergence of TNIK inhibitors in cancer therapeutics.
Yamada T; Masuda M
Cancer Sci; 2017 May; 108(5):818-823. PubMed ID: 28208209
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.
Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS
Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785
[TBL] [Abstract][Full Text] [Related]
9. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
10. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth.
Shitashige M; Satow R; Jigami T; Aoki K; Honda K; Shibata T; Ono M; Hirohashi S; Yamada T
Cancer Res; 2010 Jun; 70(12):5024-33. PubMed ID: 20530691
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
[TBL] [Abstract][Full Text] [Related]
12. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.
Chon HJ; Lee Y; Bae KJ; Byun BJ; Kim SA; Kim J
Amino Acids; 2016 Jul; 48(7):1591-9. PubMed ID: 26995282
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer.
Masuda M; Sawa M; Yamada T
Pharmacol Ther; 2015 Dec; 156():1-9. PubMed ID: 26542362
[TBL] [Abstract][Full Text] [Related]
14. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Wnt signaling pathway in colorectal cancer.
Sawa M; Masuda M; Yamada T
Expert Opin Ther Targets; 2016; 20(4):419-29. PubMed ID: 26439805
[TBL] [Abstract][Full Text] [Related]
16. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.
Yan J; Wang Q; Zou K; Wang L; Schwartz EB; Fuchs JR; Zheng Z; Wu J
Mol Med Rep; 2015 Jul; 12(1):498-502. PubMed ID: 25760445
[TBL] [Abstract][Full Text] [Related]
18. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
20. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
